FDA approves Biogen Idec’s Avonex Pen, dose titration regimen
WESTON, Mass. — The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug.
Biogen Idec said the FDA approved Avonex pen, the first single-use, once-weekly intramuscular autoinjector approved for MS, and a dose titration regimen, which gradually escalates the dose of Avonex at treatment initiation. The drug maker said the new offerings are designed to improve the treatment experience.
The Avonex pen incorporates a smaller needle and easier administration to help patients reduce anxiety about self-injection, reduces the incidence and severity of flu-like symptoms that can occur at the beginning of therapy.
No comments found
U.S. News & World Report lists pharmacist as a top job for 2012
NEW YORK — Pharmacists should see significant growth over the next decade, making the profession one of the top jobs for 2012, according to U.S. News & World Report magazine.
The publication said the occupation of a pharmacist earned the No. 3 spot on its ‘The Best Jobs of 2012’ list. The magazine cited solid employment growth — a projected 25.4% employment growth for pharmacists between 2010 and 2020, with the field adding 69,700 new jobs, according to the Bureau of Labor Statistics — along with other such key factors as the aging population, increase need for complex medicines and medication therapy management.
Salary was another factor that prompted pharmacist to earn its spot on the list: according to the Labor Department, U.S. News said, the median annual salary for a pharmacist was $111,570 in 2010. The best-paid 10% made approximately $138,620 a year, while the lowest-paid made approximately $82,090.
Click here to read the full profile.
FDA approves Hi-Tech Pharmacal epilepsy drug
AMITYVILLE, N.Y. — The Food and Drug Administration has approved a drug for epilepsy made by Hi-Tech Pharmacal, the drug maker said Wednesday.
Hi-Tech announced the approval of levetiracetam oral solution in the 100 mg-per-milliliter strength. The drug is a generic version of UCB Pharma’s Keppra oral solution and is used to treat partial onset seizures in people ages 16 years and older.
Various versions of the drug had sales of $62 million in 2011, according to IMS Health. Hi-Tech said it plans to launch the drug in May.
No comments found